Printer Friendly

IMMUNOMEDICS REPORT NEW RESULTS OF LUNG CANCER AND LYMPHOMA IMAGING AGENTS

 IMMUNOMEDICS REPORT NEW RESULTS OF
 LUNG CANCER AND LYMPHOMA IMAGING AGENTS
 WARREN, N.J., March 17 /PRNewswire/ -- Immunomedics, Inc. (NASDAQ: IMMU) today presented, for the first time, new Phase I/II clinical results of its imaging agents, ImmuRAID-(TM)CEA for lung cancer and ImmuRAID-LL2 for lymphomas, at the Cowen & Company health care industry conference in Boston. These results indicate that the ImmuRAID-CEA, which is under active review at the U.S. Food and Drug Administration for the detection of colorectal cancer, also has the capability to detect various types of lung cancer.
 Dr. David Goldenberg, chairman, presented a case study in which a patient with pulmonary fibrosis caused by prior radiation therapy demonstrated abnormal images in chest x-rays and CT scanning. Although the CEA level in this patient's blood became elevated, physicians were unable to determine the exact source of the CEA in the abnormal lung. An ImmuRAID-CEA scan pinpointed the exact location of the tumor within the lung abnormalities. Therefore, a biopsy was then performed in the precise area shown to be cancer by the ImmuRAID-CEA scan, confirming the positive antibody scan results.
 In addition, a lymphoma case study was also presented, describing the usefulness of ImmuRAID-LL2 in detecting lymphoma in various areas of a patient, particularly in the bone, which was missed by CT scanning. After the findings of the RAID scan were known, a bone scan confirmed the ImmuRAID-LL2 results. Dr. Goldenberg stated: "Our clinical trials have indicated, in cases like this, that one RAID scan was able to locate different cancer sites that otherwise would have required at least two conventional tests, such as CT scanning and bone scanning, to arrive at the same conclusion."
 Immunomedics is a biopharmaceutical company applying innovative technology in antibody selection, modification and chemistry to the development of products for the detection and treatment of cancers and infectious diseases. Integral to these products are highly specific monoclonal antibodies designed to deliver radioisotopes, chemotherapeutic agents or toxins to tumors and sites of infections.
 -0- 3/17/92
 /CONTACT: Amy Factor of Immunomedics, 908-647-5400/
 (IMMU) CO: Immunomedics Inc. ST: New Jersey IN: MTC SU:


AH-TQ -- NY049 -- 8784 03/17/92 12:49 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 17, 1992
Words:361
Previous Article:BIDERMANN RENEWS LICENSING AGREEMENT WITH BURBERRYS
Next Article:RICHEY SIGNS LETTER OF INTENT TO PURCHASE CABLE SYSTEM - CREATING THE FOURTH LARGEST PRIVATE CABLE TV COMPANY IN THE USA
Topics:


Related Articles
IMMUNOMEDICS PRESENTS CANCER THERAPEUTICS AT THE AMERICAN COLLEGE OF NUCLEAR PHYSICIANS IN SAN DIEGO
IMMUNOMEDICS REPORTS BENEFITS OF COLORECTAL CANCER IMAGING AGENT
IMMUNOMEDICS REPORTS FIRST CLINICAL RESULTS OF LYMPHOMA IMAGING AGENT
POTENTIAL NEW CANCER THERAPEUTIC DEVELOPED BY IMMUNOMEDICS AND NATIONAL CANCER INSTITUTE TEAM; RESULTS PRESENTED AT CANCER MEETING
IMMUNOMEDICS' COLORECTAL CANCER DETECTION AGENT ACCLAIMED AT SURGICAL CONGRESS: FINDINGS SHOW ACCURACY OF OVER 90 PERCENT
IMMUNOMEDICS REPORTS LYMPHOMA IMAGING AND THERAPY TEST RESULTS POSITIVE PHASE II STAGING AND THERAPY FINDINGS
IMMUNOMEDICS REPORTS ON POTENTIAL DIAGNOSTIC FOR AIDS-RELATED PNEUMONIA
Patent on positron emission tomography agents awarded to Immunomedics.
Patent awarded to Immunomedics for lymphoma treatment licensed to Amgen.
Immunomedics granted patent for Cd22 antibodies in lymphoma therapies.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters